← Browse by Condition
Medical Condition
hormone receptor positive metastatic breast cancer
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 4
NCT05362760 Phase 4
Recruiting
Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management
Enrollment
300 pts
Location
Germany, Switzerland
Sponsor
Prof. Wolfgang Janni
NCT06805812
Recruiting
Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
Enrollment
3,500 pts
Location
Italy
Sponsor
Fondazione IRCCS Istituto Nazi...